Elicio Therapeutics (ELTX) Interest Coverage Ratio (2022 - 2026)
Elicio Therapeutics' (ELTX) quarterly Interest Coverage Ratio came in at 25.44 in Q2 2026, up 51.1% on a YoY basis from 16.83 in Q2 2025, and up 2.35% quarter-over-quarter from 26.05 in Q1 2026.
Powered by 
Analysis
Elicio Therapeutics (ELTX) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has reported Interest Coverage Ratio for 5 consecutive years, with 25.44 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Coverage Ratio rose 51.1% year-over-year to 25.44; the trailing twelve-month figure through Jun 2026 stood at 24.0 (up 60.17% YoY), and the FY2025 full-year result was 33.29, up 66.33% from the prior year.
- Interest Coverage Ratio rose to 25.44 in Q2 2026 per ELTX's latest filing, from 26.05 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 5.35 in Q3 2022 and bottomed at 10771.0 in Q3 2023.
- Historically, Interest Coverage Ratio has averaged 966.28 across 5 years, with a median of 52.02 in 2025.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio sank 201132.89% in 2023, then jumped 99.3% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 64.79 in 2022, then slumped by 7147.64% to 4696.0 in 2023, then surged by 98.77% to 57.59 in 2024, then surged by 54.44% to 26.24 in 2025, then increased by 3.05% to 25.44 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 25.44, 26.05, and 26.24 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Elicio Therapeutics | 40.60 Mn | 17.10 Mn | - | -25.44 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.44 |
| Mar 31, 2026 | -26.05 |
| Dec 31, 2025 | -26.24 |
| Sep 30, 2025 | -18.88 |
| Jun 30, 2025 | -52.02 |
| Mar 31, 2025 | -61.00 |
| Dec 31, 2024 | -57.59 |
| Sep 30, 2024 | -75.50 |
| Jun 30, 2024 | -222.94 |
| Mar 31, 2024 | -284.47 |
| Dec 31, 2023 | -4,696.00 |
| Sep 30, 2023 | -10,771.00 |
| Jun 30, 2023 | -10.89 |
| Mar 31, 2023 | -22.82 |
| Dec 31, 2022 | -64.79 |
| Sep 30, 2022 | -5.35 |
| Jun 30, 2022 | -5.84 |